Meal photos, glucose context, and editable estimates in one reviewable record.
GlucIQ
Type 1 Diabetes

Islet Transplants: Who Gets Them and How They Work

· 3 min read · Reviewed by GlucIQ Clinical Review Workflow
#islet-transplant#treatment#cluster:prevention

What if the cure wasn’t a pill — but a transplant of cells that make insulin?

That’s the idea behind islet transplantation: taking insulin-making cells from a donor pancreas and putting them into someone with type 1. For some people, it works spectacularly — years without insulin injections. For others, it doesn’t last.

Here’s the honest guide.

How it works

Islet cells — the ones that make insulin — are extracted from a donated pancreas and infused into the recipient’s liver through a vein. No major surgery. The cells lodge in the liver, hook up to blood supply, and start making insulin.

It’s not like a whole-organ transplant. It’s smaller, less invasive, and it’s been done thousands of times.

Who qualifies

This is the crucial part — islet transplant is not for everyone with type 1. It’s for people with the hardest cases:

  • Severe hypoglycemia that can’t be controlled any other way (the main reason).
  • People who’ve lost the ability to feel lows — the danger zone.
  • People who’ve already had a kidney transplant (or need one) — because they’re already on anti-rejection drugs.

The reason: transplant requires immune-suppressing drugs for life, which carry real risks (infection, kidney damage, cancer risk). You only accept those risks if your diabetes is dangerous enough to justify them.

What the results look like

  • The original Edmonton protocol showed that many recipients stopped needing insulin — some for years (Shapiro et al., 2006).
  • Later, better protocols achieved longer insulin independence — with many people free of insulin for 3+ years (Bellin et al., 2012).
  • Even when insulin is needed again, the transplant usually means fewer lows and easier control — the residual cells still help.

The honest limits

  • Donor shortage. There aren’t enough donor islets for everyone.
  • Anti-rejection drugs. The lifelong immune suppression is the biggest trade.
  • It’s not a cure. Many recipients eventually need insulin again — but with much better control.
  • It doesn’t prevent the autoimmune attack on new cells; the drugs do that.

The future

Research is pushing toward stem-cell-derived islets — growing insulin-making cells in a lab instead of relying on donors. Early trials in humans have shown real promise, and an encapsulated device could one day protect the cells without heavy immune drugs.

The bottom line

Islet transplant is a powerful option for a specific group — people whose type 1 is dangerous despite the best modern care. If you’re struggling with severe, unpredictable lows, it’s worth asking your care team whether you qualify for evaluation.

References

  • Shapiro AMJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006. DOI: 10.1056/NEJMoa061267
  • Bellin MD, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation. Am J Transplant. 2012. DOI: 10.1111/j.1600-6143.2011.03977.x